Why the study?
Although national guidance mandates HbA1c and lipid profile testing during ACS admission to optimise secondary prevention, real-world adherence and inter-site variation remain suboptimal.
Does a structured system-level intervention improve compliance with guideline-directed HbA1c and lipid profile screening in acute coronary syndrome admissions?
Does a structured system-level intervention improve compliance with guideline-directed HbA1c and lipid profile screening in acute coronary syndrome admissions?
Implementing a structured, low-cost, system-level intervention significantly improves inpatient adherence to guideline-mandated HbA1c and lipid screening in acute coronary syndrome admissions.
Answers are grounded in this paper and cite their sources.
Supports structured QI interventions to improve ACS metabolic screening; extends guideline implementation evidence while leaving outcome effects open.
Background Early identification of dysglycaemia and dyslipidaemia is essential for optimising secondary prevention after acute coronary syndrome (ACS). National guidance mandates HbA1c and lipid profile testing during admission; however, real-world adherence and inter-site variation remain suboptimal. Purpose To evaluate compliance with guideline-directed metabolic screening in ACS admissions and determine whether a structured system-level intervention improves adherence and reduces variation across two hospital sites. Methods A quality improvement project was conducted across two acute hospital sites within one healthcare Trust. Two audit cycles included 200 consecutive ACS admissions (100 per cycle; 50 per site). Baseline compliance was assessed against a 100% standard. Gaps included absence of pathway integration and inter-site practice variation. A structured intervention comprising multidisciplinary education, visual prompts, audit feedback, and pathway reinforcement was implemented. Re-audit occurred three months later. Proportions were compared using Fisher’s exact test. Results Baseline compliance was low, with HbA1c testing performed in 20% and lipid profile testing in 48% of ACS admissions. Following intervention, HbA1c testing increased to 74% (+54% absolute increase; p=1.21×10-12) and lipid testing to 79% (+31% absolute increase; p=1.02×10-5), demonstrating statistically robust improvement in guideline adherence. Conclusion Failure to embed metabolic screening within ACS pathways represents a modifiable secondary prevention gap. A structured, low-cost intervention produced statistically robust improvement and reduced variation. Closing this gap at the point of ACS admission provides a scalable model for system-level cardiovascular risk optimisation.
No takes yet. Share an insight, caveat, or question.
Roy et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: